Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pexa-Vec pexastimogene devacirepvec: Phase IIb discontinued

Transgene stopped the open-label, international Phase IIb TRAVERSE trial after data from 80 patients with advanced HCC who have failed sorafenib showed that Pexa-Vec plus best

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE